Skip to content
OpenCapital
Get started

The Oncology Institute, Inc. TOI Increase (Decrease) in Other Receivables

Increase (Decrease) in Other Receivables at other companies

Inhibrx Biosciences, Inc. logo
Inhibrx Biosciences, Inc.INBX
——

Other financials

Income statement

See full
Revenue$147.4M+41.2%
Operating income-$6.5M+34.3%
Net income-$2.5M+87.3%
EPS (diluted)-$0.02+90.5%

Balance sheet

See full
Cash & equivalents$30.3M-23.8%
Total debt$104.9M+2.5%
Total equity-$16.3M-421%
Total assets$168.2M+2.6%

Cash flow

See full
Operating cash flow-$2.2M+55.6%
CapEx$1.0M+218%
Free cash flow-$3.3M+38.7%

Valuation

See full
Market cap$511.91M+133%
Enterprise value$586.58M+108%
P/S0.9×+0.4×

Profitability

See full
Operating margin-6%-2.1pp
Net margin-8%-2.7pp
FCF margin-5.1%—

Returns & leverage

See full
Return on equity-277.6%-700pp
Debt / equity20.2×+17.3×
Current ratio1.5×-0.3×

Where this comes from

Reported directly by The Oncology Institute, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherReceivables.

The official record: The Oncology Institute, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about The Oncology Institute, Inc.'s increase (decrease) in other receivables.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is The Oncology Institute, Inc.'s increase (decrease) in other receivables?
The Oncology Institute, Inc. (TOI) reported increase (decrease) in other receivables of $994K in Q1 2026.
What is the long-term trend for The Oncology Institute, Inc.'s increase (decrease) in other receivables?
Over 2 years (2021 to 2025), The Oncology Institute, Inc.'s increase (decrease) in other receivables has grown at a -41.9% compound annual growth rate (CAGR), from $863K to $291K.